Stranded Technologies Podcast

Infinita
  • 5.0 (5)
  • Entrepreneurship
  • Updated Weekly

Infinita is building early clinical access pathways for biotech acceleration such as Prospera and Montana SB535. This is the Infinita community's main channel for news, podcast episodes, event announcements & more. www.infinitacitytimes.com

  1. Aug 27

    Ep. 115: Crémieux & Soham Sankaran -The Case for Vaccine Acceleration (vacc/acc)

    Soham is the founder of PopVax, a company building vaccines faster and cheaper using AI, mRNA platforms, and a radically efficient preclinical pipeline based in India. Crémieux is a pseudonymous writer and researcher known for data-driven essays on genetics, drug regulation, and biotech policy.In this episode, we break down how vaccines actually work, why they may be one of the most powerful longevity medical interventions ever created, and how new approaches could prevent not just infections — but cancer, neurodegeneration, and chronic disease. We also explore why biotech innovation is shifting toward countries like China and India, how regulatory systems slow down progress, and what it would take to radically accelerate drug development worldwide. This is a conversation about science, institutions, and the future of human health. More about Soham’s work: * PopVax * Soham on X More about Crémieux’s work: * Cremieux Substack * Crémieux on X This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 115: Crémieux & Soham Sankaran -The Case for Vaccine Acceleration (vacc/acc)

  2. Aug 14

    Ep. 114: The Ultimate Guide to Montana SB535: A US State’s Path to Accelerate Biotech & Patient Access

    In this episode, Niklas Anzinger sits down with Stephen Martin, U.S. Lead at Infinita and Operations Lead of the Montana Experimental Treatment Review Board (ETRB), to explore what could become a new model for biotech development and patient access in the United States. Montana SB 535, is a new framework allowing eligible post-Phase 1 experimental treatments to reach patients under regulated oversight with special clinic licenses and an expert review board. Stephen explains why traditional Right-to-Try and expanded access programs have struggled to scale, and how Montana could change the economics by allowing biotechs to generate real-world evidence, treat patients, and create revenue earlier in the development process. They discuss how the pathway works in practice, who qualifies, opportunities for biotech companies and physicians, the relationship between state and federal regulation, the FDA’s role, and whether Montana could ultimately provide a blueprint for accelerating drug development across the United States. More on this topic: * Scott Alexander on the Aduhelm Approval * Jared Rhoads on X This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 114: The Ultimate Guide to Montana SB535: A US State’s Path to Accelerate Biotech & Patient Access

  3. Jul 30

    Ep. 113. Reason on Clinical Trials, Medical Tourism, and the Data the FDA Won’t See

    Reason, co-founder and CEO of Repair Biotechnologies and a longevity industry veteran with a background in astrophysics, joins us to talk about what it actually takes to test a therapy on humans, and why the system built to protect patients often keeps the best evidence hidden. He breaks down why investors backing gene and cell therapies care more about a drug’s earning potential than whether it works, and why treatments already in use could be quietly adding years to human lifespan without anyone confirming it. Drawing on his own experience as a trial participant in Roatán, he also explains why Australia has become a faster, cheaper alternative for clinical trials, and how much of that gap comes down to culture rather than actual safety. More about Reason’s work: * Fight Aging! This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 113. Reason on Clinical Trials, Medical Tourism, and the Data the FDA Won’t See

  4. Jul 16

    Ep. 112: Tim Urban on Startup Cities, AI Safety, Longevity, and Building Better Societies

    Tim Urban, creator of Wait But Why and the mind behind one of the most-watched TED Talks of all time, joins us to talk about why progress does not happen automatically. In this episode, he discusses the Space Race, longevity, AI safety, startup cities, and the social conditions that allow new ideas to survive. Tim explains why some technologies move fast while others stall for decades, why the best communities treat ideas like experiments, and why the future may depend less on prediction and more on building better environments for progress. More about Tim Urban’s work: * Tim Urban’s X * What’s Our Problem?: A Self-Help Book for Societies This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 112: Tim Urban on Startup Cities, AI Safety, Longevity, and Building Better Societies

  5. Jun 22

    Ep. 111: Antonio García Martínez on Crypto, Network States, and Building New Cities

    Antonio Garcia Martinez is a writer, entrepreneur, and director at Base, Coinbase’s Ethereum L2. Before that he sold a startup to Twitter, worked on ads at Facebook, and wrote Chaos Monkeys, his memoir about the early ad-tech world. This session was recorded live in the Infinity Dome in Prospera. Antonio explains why crypto is not just a new financial system. It is a direct challenge to one of the oldest powers of the state: controlling money and deciding who owns what. If you can send USDC on Base to anyone in the room in less than a second for less than a cent, and no bank or government can stop it, the foundations of the current world start to shift. From there, we move into the friction between digital freedom and physical geography. Antonio, Niklas and Eric talk about Próspera as a real world network state, why San Francisco stays a magnet even when it fails on the basics, and which places have the energy to become new tech hubs. Miami, Dubai, Singapore, and the American West all come up as examples. They also look at the hard questions: how to build a business model for charter cities, how the US might allow Prospera-style zones through interstate compacts, and what needs to change in education and citizenship to attract long-term residents. This is a conversation about the future of crypto, but also about the future of how people live, build, and move. It is one of the clearest snapshots of where the network state movement is heading. More about Antonio’s work: * Website * Books * Linkedin Explore Infinita City: * Explore the Archive: The Infinita City Times * Visit Infinita City * Join the Builders’ Hub on Telegram * Follow Infinita City on X This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 111: Antonio García Martínez on Crypto, Network States, and Building New Cities

  6. Jun 4

    Ep. 110: Tomas Pueyo & Trey Goff On The Next Silicon Valley Might Be A New Country

    In this episode, the famous blogger Tomas Pueyo (Uncharted Territories) interviews Trey Goff (Chief of Staff & Head of Public Policy at Prospera) & Niklas Anzinger (Founder & CEO of Infinita City). The interview is part of the research that Tomas did for a deep piece on “The Cold Start Problem of New Cities”, as Niklas & Trey are two of the most experienced practitioners in this emerging industry. This ends up in a fascinating conversation about how new governance applied to time & place, culminating in new cities, could unlock entirely new models of human progress. More about Tomas Pueyo’s work: * 20 Ideas to Grow New Communities * Tomas Pueyo’s X More about Trey Goff’s work: * Trey Goff’s X This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 110: Tomas Pueyo & Trey Goff On The Next Silicon Valley Might Be A New Country

  7. May 21

    Ep. 109: Jonathan Anomaly on The Future of Human Enhancement, Genetic Selection & Startup Societies

    In this episode, Jonathan Anomaly joins us to discuss the collapse of trust in modern institutions, the rise of tribal politics, and why liberty increasingly depends on exit rather than persuasion.We explore embryo selection, genetics, rational irrationality, startup societies, academia, media manipulation, and the future of liberalism in an age of polarization.From controversial ideas to practical entrepreneurship, this conversation dives into what happens when people stop asking permission and start building alternatives. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 109: Jonathan Anomaly on The Future of Human Enhancement, Genetic Selection & Startup Societies

  8. May 8

    Ep. 108: The Buck Inst. President, Eric Verdin, on Pathways to Life Extension Acceleration: Alternative Pathways and Radical Hopium vs. Scientific Realism

    In this episode, we sit down with Eric Verdin, CEO of the Buck Institute, one of the world’s leading institutes dedicated to aging and longevity research.Eric has often been associated with a more rigorous and incremental approach to extending human lifespan, focused on scientific validation, measurable progress, and improving healthspan before chasing more radical ambitions. In contrast, the broader life extension movement has become known for pushing bold visions of indefinite lifespan and extreme human enhancement.But as this conversation unfolds, it becomes clear that these approaches are far less opposed than they may seem.We explore the relationship between moonshots and incremental progress, the role of scientific rigor in advancing longevity, and the institutional incentives that often reward performative radicalism over real-world results. The conversation also touches on regulation, public perception, and the challenge of turning longevity from a speculative idea into a field capable of delivering tangible benefits to people today.Rather than framing ambition and rigor as competing forces, this episode examines why both are necessary to meaningfully move the field forward. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

    Ep. 108: The Buck Inst. President, Eric Verdin, on Pathways to Life Extension Acceleration: Alternative Pathways and Radical Hopium vs. Scientific Realism
See All (118)

Ratings & Reviews

5
out of 5
5 Ratings

About

Infinita is building early clinical access pathways for biotech acceleration such as Prospera and Montana SB535. This is the Infinita community's main channel for news, podcast episodes, event announcements & more. www.infinitacitytimes.com

Information

You Might Also Like